Tango Therapeutics, Inc. (TNGX)
$24.17+1.51%Close
SELLRECOVERY · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $3.0B
- Beta
- 1.17
- P/E (TTM)
- -25.76
- Short % float
- 54.26%
- Days to cover
- 12.5
- SI change
- +6.3%
- 1W
- +4.72%
- 1M
- +1.64%
- vs SPY 1W
- +4.30%
- vs SPY 1M
- -0.42%
Industry peers
FMP comparable companies · ranked by market cap
- RVMDSELLRevolution Medicines, Inc.$40.3BRECOVERYQ 30$189.76+2.21%
- ERASSELLErasca, Inc.$5.6BRECOVERYQ 4$16.03-3.56%
- RLAYSELLRelay Therapeutics, Inc.$3.9BRECOVERYQ 3$17.88+0.56%
- IDYASELLIDEAYA Biosciences, Inc.$3.4BBEARQ 25$36.11-0.14%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.35-0.85%
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$5.00-2.00%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on TNGX?
- LOPJLB’s latest quantitative signal on Tango Therapeutics, Inc. (TNGX) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is TNGX in?
- Tango Therapeutics, Inc. (TNGX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Tango Therapeutics, Inc. (TNGX) do?
- Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphoryla…